Key Points
- Director Sharon Wienbar bought 924 Enovis shares at an average price of $26.98, spending about $24,930 and increasing her holdings by 2.16% to 43,777 shares.
- Enovis reported quarterly EPS of $0.88, beating the $0.77 consensus, while revenue of $558.73 million slightly exceeded estimates and rose 1.8% year over year.
- Analysts give the stock a consensus Moderate Buy rating, with an average price target of $38.62.
Enovis Corporation (NYSE:ENOV - Get Free Report) Director Sharon Wienbar bought 924 shares of Enovis stock in a transaction dated Monday, November 9th. The stock was purchased at an average price of $26.98 per share, with a total value of $24,929.52. Following the completion of the purchase, the director owned 43,777 shares in the company, valued at $1,181,103.46. This trade represents a 2.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Enovis Price Performance
Shares of ENOV opened at $28.25 on Wednesday. The business's fifty day moving average is $20.05 and its 200 day moving average is $23.14. Enovis Corporation has a 12-month low of $16.70 and a 12-month high of $32.41. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.63 billion, a P/E ratio of 8.44 and a beta of 1.31.
Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.11. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm had revenue of $558.73 million for the quarter, compared to the consensus estimate of $557.12 million. During the same quarter in the prior year, the company posted $0.75 earnings per share. The business's revenue was up 1.8% on a year-over-year basis. Sell-side analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current fiscal year.
Institutional Trading of Enovis
Institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc lifted its holdings in Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock worth $25,000 after acquiring an additional 1,174 shares during the period. Allworth Financial LP bought a new position in Enovis in the 2nd quarter valued at $36,000. Integrated Wealth Concepts LLC bought a new position in Enovis during the second quarter valued at about $39,000. Public Employees Retirement System of Ohio purchased a new position in Enovis in the second quarter valued at about $48,000. Finally, SBI Securities Co. Ltd. purchased a new position in Enovis in the third quarter valued at about $55,000. 98.45% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ENOV has been the topic of a number of analyst reports. Citizens Jmp lowered their target price on shares of Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a report on Wednesday, September 2nd. Citigroup reissued a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Wall Street Zen upgraded Enovis from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. BMO Capital Markets set a $27.00 target price on Enovis in a research report on Tuesday, September 1st. Finally, Needham & Company LLC upped their price target on Enovis from $34.00 to $38.00 and gave the stock a "buy" rating in a report on Thursday, November 5th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $38.62.
Check Out Our Latest Stock Report on ENOV
Enovis Company Profile
(
Get Free Report)
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
